Compare
Perrigo Co PLC vs Elanco Animal Health Inc vs Alnylam Pharmaceuticals, Inc. vs BioMarin Pharmaceutical Inc
| Latest fiscal year | Perrigo Co PLC PRGO | Elanco Animal Health Inc ELAN | Alnylam Pharmaceuticals, Inc. ALNY | BioMarin Pharmaceutical Inc BMRN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.25B | $4.71B | $3.71B | $3.22B |
| Revenue growth (YoY) | -2.8% | +6.2% | +65.2% | +12.9% |
| Gross margin | 35.1% | 55.0% | 81.8% (computed) | 77.7% (computed) |
| Operating margin | -26.4% | n/a | 13.5% | 12.7% |
| Net margin | -33.5% | -4.9% | 8.4% | 10.8% |
| Net income | -$1.43B | -$232.00M | $313.75M | $348.90M |
| EPS (Diluted) | -$10.29 | -$0.47 | $2.33 | $1.80 |
| Operating cash flow | $238.50M | $560.00M | $524.08M | $827.99M |
| Free cash flow | $145.10M | $284.00M | $465.38M | $724.96M |
| Cash & equivalents | n/a | $545.00M | $1.66B | $1.31B |
| Total assets | $8.54B | $13.36B | $4.97B | $7.59B |
| Total liabilities | $5.60B | $6.81B | $4.18B | $1.51B |
| Shareholders' equity | $2.94B | $6.55B | $789.18M | $6.09B |
| Return on year-end equity | -48.6% | -3.5% | 39.8% | 5.7% |
| Shares outstanding | 137.60M | 496.98M | 132.38M | 192.30M |
Revenue, most recent five fiscal years
| Fiscal year | Perrigo Co PLC | Elanco Animal Health Inc | Alnylam Pharmaceuticals, Inc. | BioMarin Pharmaceutical Inc |
|---|---|---|---|---|
| Latest | $4.25B Ended 2025-12-31 | $4.71B Ended 2025-12-31 | $3.71B Ended 2025-12-31 | $3.22B Ended 2025-12-31 |
| 1 year earlier | $4.37B Ended 2024-12-31 | $4.44B Ended 2024-12-31 | $2.25B Ended 2024-12-31 | $2.85B Ended 2024-12-31 |
| 2 years earlier | $4.66B Ended 2023-12-31 | $4.42B Ended 2023-12-31 | $1.83B Ended 2023-12-31 | $2.42B Ended 2023-12-31 |
| 3 years earlier | $4.45B Ended 2022-12-31 | $4.41B Ended 2022-12-31 | $1.04B Ended 2022-12-31 | $2.10B Ended 2022-12-31 |
| 4 years earlier | $4.14B Ended 2021-12-31 | $4.76B Ended 2021-12-31 | $844.29M Ended 2021-12-31 | $1.85B Ended 2021-12-31 |